Navigation Links
Shire plc: Continued Strong Product Sales Performance in Q3: On Track to Deliver Significant 2011 Earnings Growth
Date:10/28/2011

discStyle" type="disc">
  • On August 24, 2011 Shire announced its preliminary analysis of the top-line results from ABH's Phase 3 pivotal trial of DERMAGRAFT in subjects with VLU. The international pivotal trial was designed as a prospective, multicenter, randomized, controlled clinical study to assess the product's safety and efficacy in the promotion of healing VLU. The preliminary analysis of the data was that the trial did not meet the primary endpoint mutually agreed with the FDA and European Medicine Agency.

  •  

    VYVANSE® - for the treatment of Attention Deficit Hyperactivity Disorder ("ADHD")

    • On October 21, 2011 Shire reported positive top line results of the first European Phase 3 study of once-daily lisdexamfetamine dimesylate ("LDX") in children and adolescents aged 6 to 17 years with ADHD. The study, conducted at 48 sites across Europe, demonstrated that a once-daily morning dose of LDX resulted in positive efficacy results on the primary as well as key secondary endpoints compared to placebo, and a safety profile consistent with the known effects of amphetamine treatment and previous LDX trials. In the study, patients were randomized to receive LDX, osmotic-controlled extended-release methylphenidate ("OROS-MPH"; marketed as CONCERTA® and CONCERTA XL® by Johnson & Johnson) or placebo, over a period of seven weeks. The CONCERTA arm was included in order to provide data versus the current European standard of care as it is often required for approval and to support appropriate reimbursement. The primary measure was the change in total score of the ADHD-RS-IV of LDX versus placebo with OROS-MPH included as an active control.


     

    VYVANSE - for the treatment of inadequate response in Major Depressive Disorder ("MDD")

    • Today, in the live conference call for investors
      '/>"/>

    SOURCE Shire plc
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

    Related biology technology :

    1. NHS Northamptonshire Chief Executive John Parkes Accepts Visiting Professorship
    2. FDA Approves Shires FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE)
    3. Shires Quarterly Revenues Grow by 25% to $1 Billion for the First Time
    4. Shire Files Lawsuits Against Watson and Roxane for Infringement of VYVANSE(R) (lisdexamfetamine dimesylate) Patents
    5. Shire Presents Data at ACMG for Fabry and Gaucher Patients Who Switched to Replagal® (agalsidase alfa) and VPRIV® (velaglucerase alfa for injection)
    6. Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse(R) (lisdexamfetamine dimesylate) Capsules as Adjunctive Treatment in Major Depressive Disorder
    7. Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging
    8. Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period
    9. Reportlinker Adds Shire plc: PharmaVitae Profile
    10. Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease
    11. Shire plc - Statement re ProAmatine
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/18/2014)... , Sept. 18, 2014 /PRNewswire-iReach/ -- DeepResearchReports.com ... China Acetic Acid Industry" and "2014 Deep Research ... reports to its research database. Photo ... Deep Research Report on Global and China Acetic ... report on China and ...
    (Date:9/18/2014)... 18, 2014  Health Enhancement Products, Inc. (OTCQB: HEPI), a ... bioactive compounds and metabolic processes, is pleased to announce the ... directors. Ms. Nola E. Masterson , a ... board effective September 17, 2014. "We,re very ... our board," states Andrew Dahl , President and CEO. ...
    (Date:9/18/2014)... (PRWEB) September 18, 2014 Texas ... John Sharp, Texas A&M Health Science Center CEO ... Department of Health and Human Services (HHS), State ... a national pandemic influenza vaccine manufacturing facility in ... an anchor for the Texas A&M Biocorridor – ...
    (Date:9/18/2014)... Research and Markets has announced ... Cell Industry Report, 2014-2017" report to their offering. ... that can differentiate into specialized cells and can divide ... therapy can be applied to treatment of cardiovascular diseases, ... diseases, damage or lesion of liver, kidney and other ...
    Breaking Biology Technology:Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 2Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 3Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 4Health Enhancement Announces New Board Member In Advance Of Annual Shareholder Meeting 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 3Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 4Global and Chinese Stem Cell Industry Report, 2014-2017 2Global and Chinese Stem Cell Industry Report, 2014-2017 3
    ... Medline Industries, Inc., the,nation,s largest privately held ... it has signed a three-year agreement to,purchase mouth ... products,for personal care, infection control and diagnostic use ... rinse in the healthcare market, we are,happy to ...
    ... 21st Century Health Care Forum discusses the future of Continuing ... ... June 2 Accredited online nursing courses,are replacing traditional classroom-based courses, ... in,their credentialing options., Ann Johnson, CEO of Wild Iris Medical ...
    ... PRINCETON, N.J., June 2 IntegriChain, Inc. today,announced ... the Company,s,Board of Directors, further bolstering its position ... Mr. Bailye, 54, recently retired from his ... Dendrite was acquired by French information,provider Cegedim. Under ...
    Cached Biology Technology:Medline Signs 3-Year Purchasing Agreement for Mouth Rinse From Chester Labs 2Modernizing Continuing Education With Online Courses 2IntegriChain Appoints John Bailye to Its Board of Directors 2
    (Date:9/19/2014)... years has adapted to the arctic cold, and then you ... for you. , This is happening to the small white ... called nonylphenol, comes from the use of certain detergents, pesticides ... disruptor, but when entering the worm it has another dangerous ... in its body from cold damage. , Enchytraeus albidus ...
    (Date:9/18/2014)... A sleep-promoting circuit located deep in the primitive brainstem ... by researchers at Harvard School of Medicine and the ... this is only the second "sleep node" identified in ... necessary and sufficient to produce deep sleep. , Published ... study demonstrates that fully half of all of the ...
    (Date:9/18/2014)... a "frequent flyers" program, fruit flies surely would be ... hosted increasing numbers of fruit fly research studies. One ... April, and another is scheduled launch to the station ... in December. , Fruit flies are biomedical research models ... Model organisms can reveal the basis for health and ...
    Breaking Biology News(10 mins):Environmental pollutants make worms susceptible to cold 2Environmental pollutants make worms susceptible to cold 3No sedative necessary: Scientists discover new 'sleep node' in the brain 2Buzzing with activity: Fruit flies orbit Earth for science 2Buzzing with activity: Fruit flies orbit Earth for science 3Buzzing with activity: Fruit flies orbit Earth for science 4
    ... at Albert Einstein College of Medicine of Yeshiva University ... from the Bill & Melinda Gates Foundation for their ... are Arturo Casadevall , M.D., Ph.D., who is working to ... , Ph.D., and Joan Berman , Ph.D., for their work ...
    ... Joseph G. Morse , a professor of entomology ... year,s recipient of the California Citrus Quality Council ... of "his steadfast dedication in the field of entomology ... For more than three decades, Morse has provided ...
    ... led by the University of Colorado Boulder has been awarded $9.2 ... research modifying E. coli to produce biofuels such as ... we have worked on for the past decade to the next ... and Sustainable Energy Institute, or RASEI. "In this project, we will ...
    Cached Biology News:Einstein researchers receive 2 Grand Challenges Explorations grants to combat HIV and TB 2Einstein researchers receive 2 Grand Challenges Explorations grants to combat HIV and TB 3UC Riverside entomologist recognized for research in citrus entomology 2CU-led team receives $9.2 million DOE grant to engineer E. coli into biofuels 2
    Human peripheral blood eosinophils, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Granulocytes...
    Human peripheral blood PBMCs, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood PBMC and T Cells...
    Cord blood endothelial progenitor cells, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood Progenitor Cells...
    Human plasmacytoid dendritic cells, BDCA-4+, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Dendritic Cells and EPCs...
    Biology Products: